MoonLake Immunotherapeutics
MLTX- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001821586
In the last 90 days, MoonLake Immunotherapeutics insiders filed 0 open-market purchases and 6 sales; 172 institutions reported holding it in 13F filings for Q2 2026, worth $1.43B in total; no superinvestor holds it.
13F holders, Q2 2021
Institutional positions in MoonLake Immunotherapeutics as of Jun 30, 2021. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 46
- +4 vs. Q1 2021
- Shares held
- 11.2M
- +526.2K (+4.9%) vs. Q1 2021
- Total value
- $115.8M
- +$6.86M (+6.3%) vs. Q1 2021
- New holders
- 6
- 7 more added
- Sold out
- 2
- 9 more reduced
Compare with Q1 2021: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting MLTX on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 172 | $1.43B |
| Q1 2026 | 147 | $1.17B |
| Q4 2025 | 130 | $742.9M |
| Q3 2025 | 134 | $269.7M |
| Q2 2025 | 130 | $2.77B |
| Q1 2025 | 136 | $2.34B |
| Q4 2024 | 116 | $3.43B |
| Q3 2024 | 109 | $3.14B |
| Q2 2024 | 111 | $2.67B |
| Q1 2024 | 114 | $2.99B |
| Q4 2023 | 125 | $3.53B |
| Q3 2023 | 118 | $3.21B |
| Q2 2023 | 83 | $2.86B |
| Q1 2023 | 43 | $843.2M |
| Q4 2022 | 33 | $396.4M |
| Q3 2022 | 24 | $291.4M |
| Q2 2022 | 23 | $190.1M |
| Q1 2022 | 27 | $123.4M |
| Q4 2021 | 45 | $112.8M |
| Q3 2021 | 43 | $111.1M |
| Q2 2021 | 46 | $115.8M |
| Q1 2021 | 42 | $108.9M |
Institutions, Q2 2021
Shares, value and share of portfolio for each institution holding MoonLake Immunotherapeutics; share changes are against Q1 2021.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Adage Capital Partners GP, L.L.C. | 1,011,589 | $10.5M | 0.02% | 00.0% | Unchanged |
| Price T Rowe Associates Inc | 756,303 | $7.81M | 0.00% | −35,982−4.5% | Reduced |
| RTW Investments, LP | 750,000 | $7.76M | 0.12% | 00.0% | Unchanged |
| BlackRock Inc. | 747,863 | $7.74M | 0.00% | −2,290−0.3% | Reduced |
| Ra Capital Management, L.P. | 700,000 | $7.25M | 0.12% | 00.0% | Unchanged |
| Citadel Advisors LLC | 691,731 | $7.15M | 0.01% | −1,636−0.2% | Reduced |
| Wellington Management Group LLP | 516,296 | $5.33M | 0.00% | −10,429−2.0% | Reduced |
| Ghost Tree Capital, LLC | 500,000 | $5.17M | 1.62% | 00.0% | Unchanged |
| Staley Capital Advisers Inc | 500,000 | $5.17M | 0.27% | +200,000+66.7% | Added |
| Cormorant Asset Management, LP | 430,000 | $4.45M | 0.17% | 00.0% | Unchanged |
| Avidity Partners Management LP | 400,000 | $4.14M | 0.11% | 00.0% | Unchanged |
| Boxer Capital, LLC | 400,000 | $4.13M | 0.15% | 00.0% | Unchanged |
| Octagon Capital Advisors LP | 400,000 | $4.13M | 0.86% | 00.0% | Unchanged |
| Finepoint Capital LP | 350,000 | $3.62M | 0.68% | +350,000 | New |
| Alyeska Investment Group, L.P. | 320,000 | $3.31M | 0.04% | 00.0% | Unchanged |
| Bain Capital Life Sciences Investors, LLC | 250,000 | $2.59M | 0.17% | 00.0% | Unchanged |
| Altium Capital Management LP | 250,000 | $2.59M | 0.60% | 00.0% | Unchanged |
| Foresite Capital Management V, LLC | 250,000 | $2.59M | 1.02% | 00.0% | Unchanged |
| Tekla Capital Management LLC | 250,000 | $2.58M | 0.08% | 00.0% | Unchanged |
| Silverarc Capital Management, LLC | 234,020 | $2.42M | 1.27% | +5,535+2.4% | Added |
| EcoR1 Capital, LLC | 200,000 | $2.07M | 0.08% | 00.0% | Unchanged |
| Rock Springs Capital Management LP | 154,500 | $1.60M | 0.03% | 00.0% | Unchanged |
| 683 Capital Management, LLC | 150,000 | $1.55M | 0.08% | 00.0% | Unchanged |
| BlueCrest Capital Management Ltd | 150,000 | $1.55M | 0.05% | 00.0% | Unchanged |
| Consonance Capital Management LP | 150,000 | $1.55M | 0.19% | 00.0% | Unchanged |
| Picton Mahoney Asset Management | 70,000 | $725.0K | 0.03% | +70,000 | New |
| Magnetar Financial LLC | 61,204 | $632.0K | 0.01% | −2,747−4.3% | Reduced |
| Glazer Capital, LLC | 57,849 | $599.0K | 0.01% | +56,748+5,154.2% | Added |
| Millennium Management LLC | 55,735 | $577.0K | 0.00% | +35,735+178.7% | Added |
| Logos Global Management LP | 50,000 | $518.0K | 0.04% | −150,000−75.0% | Reduced |
| Prelude Capital Management, LLC | 50,000 | $518.0K | 0.03% | +50,000 | New |
| Maven Securities LTD | 50,000 | $513.0K | 0.05% | 00.0% | Unchanged |
| Janus Henderson Group PLC | 48,263 | $497.0K | 0.00% | 00.0% | Unchanged |
| TD Asset Management Inc | 44,766 | $444.0K | 0.00% | 00.0% | Unchanged |
| Meridian Wealth Management, LLC | 27,000 | $279.0K | 0.04% | +8,100+42.9% | Added |
| Radcliffe Capital Management, L.P. | 25,131 | $260.0K | 0.01% | +5,131+25.7% | Added |
| Exos Asset Management LLC | 25,100 | $260.0K | 0.13% | +20,100+402.0% | Added |
| ExodusPoint Capital Management, LP | 25,000 | $259.0K | 0.00% | 00.0% | Unchanged |
| Nomura Holdings Inc | 24,949 | $255.0K | 0.00% | −51−0.2% | Reduced |
| D. E. Shaw & Co., Inc. | 23,013 | $238.0K | 0.00% | +23,013 | New |
| Caxton Corp | 16,009 | $165.0K | 0.11% | 00.0% | Unchanged |
| HRT Financial LP | 14,258 | $147.0K | 0.00% | 00.0% | Unchanged |
| Panagora Asset Management Inc | 7,212 | $74.0K | 0.00% | −41−0.6% | Reduced |
| Morgan Stanley | 5,900 | $61.0K | 0.00% | −10.0% | Reduced |
| UBS Group AG | 374 | $4.00K | 0.00% | +374 | New |
| Tower Research Capital LLC (TRC) | 17 | $0 | 0.00% | +17 | New |
| HealthCor Management, L.P. | 0 | $0 | 0.00% | −60,027−100.0% | Sold out |
| Suvretta Capital Management, LLC | 0 | $0 | 0.00% | −35,344−100.0% | Sold out |